Merck KGaA (FRA:MRK) PT Set at €108.00 by Sanford C. Bernstein

Merck KGaA (FRA:MRK) has been given a €108.00 ($125.58) price objective by research analysts at Sanford C. Bernstein in a report released on Tuesday, June 4th, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Sanford C. Bernstein’s price objective suggests a potential upside of 17.44% from the stock’s previous close.

A number of other analysts also recently issued reports on MRK. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Independent Research set a €106.00 ($123.26) price target on Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, May 14th. Warburg Research set a €103.00 ($119.77) price target on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, March 27th. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, May 13th. Finally, Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of €100.53 ($116.89).

Shares of FRA MRK traded down €0.76 ($0.88) during midday trading on Tuesday, reaching €91.96 ($106.93). 512,921 shares of the stock traded hands. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72). The stock has a 50 day moving average of €91.15.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: Do You Need a Fiduciary?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.